No quarterly revenue total was found in NEXTCURE, INC's SEC filings.
Nextcure, Inc (NXTC) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $15.3 million in cash and investments and $4.7 million in total debt.
Revenue
—
Net income
$-14.89M
+44.4% vs year-ago quarter
Operating cash flow
$-9.71M
+57.2% vs year-ago quarter
Free cash flow
$-7.00M
+39.8% vs prior quarter
EPS
$-2.80
+75.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
4.58M
+71.0% vs year-ago quarter
Net cash
$10.59M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NXTC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Baltimore, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1661059
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$15.1M | -$10.1M | -$9.8M | -$8.9M | -$27.3M |
| Net income | -$14.9M | -$9.8M | -$9.4M | -$8.6M | -$26.8M |
| Diluted EPS | -$2.80 | -$1.87 | -$2.38 | -$3.22 | -$11.29 |
| Operating cash flow | -$9.7M | -$13.4M | -$7.6M | -$6.3M | -$22.7M |
| Total assets | $22.6M | $38.0M | $50.2M | $39.6M | $47.7M |
| Total liabilities | $10.5M | $11.3M | $15.2M | $16.0M | $16.0M |
| Stockholders' equity | $12.1M | $26.7M | $34.9M | $23.6M | $29.6M |
| Cash and investments | $15.3M | $15.2M | $26.0M | $7.3M | $4.9M |
| Total debt | $4.7M | $4.9M | $5.2M | $5.4M | $5.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 30, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Sep 25, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 3, 2026 | Sep 3, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Exit or restructuring costs, Change in control, Officer or director change, Regulation FD disclosure, Other events
|
Jul 14, 2026 | Jul 14, 2026 |
All 394 Nextcure, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.